Literature DB >> 277252

Clinical experience with misonidazole.

S Dische, M I Saunders.   

Abstract

A total of 62 patients with advanced tumours have now been treated by a fractionated course of radiotherapy, with misonidazole. The prime purpose of the administration of the drug to these patients was to determine safe dosage and suitable regimes for use in clinical radiotherapy. The reaction of normal tissues did not seem enhanced but there was an impression of increased tumour response.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 277252      PMCID： PMC2149429     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN： 0306-9443


  5 in total

1.  Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.

Authors:  A J Gray; S Dische; G E Adams; I R Flockhart; J L Foster
Journal:  Clin Radiol       Date:  1976-04       Impact factor: 2.350

2.  The hyperbaric oxygen chamber in the radiotherapy of carcinoma of the uterine cervix.

Authors:  S Dische
Journal:  Br J Radiol       Date:  1974-02       Impact factor: 3.039

3.  Clinical testing of the radiosensitiser Ro-07-0582. III. Response of tumours.

Authors:  R H Thomlinson; S Dische; A J Gray; L M Errington
Journal:  Clin Radiol       Date:  1976-04       Impact factor: 2.350

4.  Clinical testing of the radiosensitiser Ro-07-0582. II. Radiosensitisation of normal and hypoxic skin.

Authors:  S Dische; A J Gray; G D Zanelli
Journal:  Clin Radiol       Date:  1976-04       Impact factor: 2.350

5.  Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

Authors:  S Dische; M I Saunders; M E Lee; G E Adams; I R Flockhart
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640
  5 in total
  2 in total

1.  The search for new hypoxic cell radiosensitizers.

Authors:  C M Mansfield; B F Kimler; C C Cheng; I L Abrahams; E G Podrebarac; P J Wittek; E K Reddy
Journal:  J Natl Med Assoc       Date:  1980-08       Impact factor: 1.798

2.  Cytotoxicity of metronidazole (Flagyl) and misonidazole (Ro-07-0582): enhancement by lactate.

Authors:  J S Mahood; R L Willson
Journal:  Br J Cancer       Date:  1981-03       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.